Deutsche Bank Ag\ Summit Therapeutics Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 397,678 shares of SMMT stock, worth $8.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

397,678

Previous 47,693 733.83%

Holding current value

$8.73 Million

Previous $372,000 2241.13%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$6.89 - $31.93 $2.41 Million - $11.2 Million	349,985 Added 733.83%	397,678 $8.71 Million
Q2 2024 Aug 14, 2024	SELL	$2.39 - $10.92 $56,960 - $260,256	-23,833 Reduced 33.32%	47,693 $372,000
Q1 2024 May 15, 2024	SELL	$2.55 - $5.07 $4,363 - $8,674	-1,711 Reduced 2.34%	71,526 $296,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $13,171 - $22,320	7,887 Added 12.07%	73,237 $191,000
Q3 2023 Nov 09, 2023	BUY	$1.54 - $2.42 $18,011 - $28,304	11,696 Added 21.8%	65,350 $122,000
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $70,823 - $150,767	53,654 New	53,654 $134,000
Q2 2022 Aug 11, 2022	SELL	$0.92 - $2.38 $13,165 - $34,057	-14,310 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.0 - $3.45 $3,396 - $5,858	-1,698 Reduced 10.61%	14,310 $35,000
Q4 2021 Feb 11, 2022	BUY	$2.45 - $5.64 $2,082 - $4,794	850 Added 5.61%	16,008 $43,000
Q3 2021 Nov 04, 2021	BUY	$4.83 - $8.27 $8,718 - $14,927	1,805 Added 13.52%	15,158 $76,000
Q2 2021 Aug 11, 2021	BUY	$5.15 - $8.46 $68,721 - $112,890	13,344 Added 148266.67%	13,353 $100,000
Q1 2021 May 13, 2021	BUY	$5.17 - $11.19 $46 - $100	9 New	9 $0

Others Institutions Holding SMMT

# of Institutions

201

Shares Held

76.4M

Call Options Held

2.01M

Put Options Held

2.83M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.42B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account